Cited by 242Parkinson's Disease Mechanisms and TreatmentsDementia and Cognitive Impairment ResearchNuclear Receptors and Signaling

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study

De Pablo-Fernandez, Eduardo, Goldacre, Raph, Pakpoor, Julia, Noyce, Alastair J., Warner, Thomas T.·2018·Neurology

DOI 10.1212/wnl.0000000000005771

Open this paper in CoChat — free account

Abstract

Objective To investigate the association between type 2 diabetes mellitus (T2DM) and subsequent Parkinson disease (PD). Methods Linked English national Hospital Episode Statistics and mortality data (1999–2011) were used to conduct a retrospective cohort study. A cohort of individuals admitted for hospital care with a coded diagnosis of T2DM was constructed, and compared to a reference cohort. Subsequent PD risk was estimated using Cox regression models. Individuals with a coded diagnosis of cerebrovascular disease, vascular parkinsonism, drug-induced parkinsonism, and normal pressure hydrocephalus were excluded from the analysis. Results A total of 2,017,115 individuals entered the T2DM cohort and 6,173,208 entered the reference cohort. There were significantly elevated rates of PD following T2DM (hazard ratio [HR] 1.32, 95% confidence interval [CI] 1.29–1.35; p < 0.001). The relative increase was greater in those with complicated T2DM (HR 1.49, 95% CI 1.42–1.56) and when comparing younger individuals (HR 3.81, 95% CI 2.84–5.11 in age group 25–44 years). Conclusions We report an increased rate of subsequent PD following T2DM in this large cohort study. These findings may reflect shared genetic predisposition and/or disrupted shared pathogenic pathways with potential clinical and therapeutic implications.

Integrity signals

Registry

Crossref · 10.1212/wnl.0000000000005771

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial
Athauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 2×
“A recent doubleblind trial involving 62 patients with PD randomly assigned to placebo or exenatide 2-mg weekly injections showed positive and persistent effects on motor symptoms measured by section 3 of the Movement Disorder Society–Unified Parkinson’s Disease Rating Scale.(9)Whether the effect is secondary to sympto…”
BackgroundSelf-citation
Meta‐analysis of early nonmotor features and risk factors for Parkinson disease
Noyce, A. J., Bestwick, J. P., Silveira‐Moriyama, L., Hawkes, C. H., Giovannoni, G., Lees, A. J., & Schrag, A. E. (2012) · Annals of Neurology · doi:10.1002/ana.23687 · Cited by 834
Self-citation
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Diabetes and Risk of Parkinson’s Disease
Xu, Q., Park, Y., Huang, X., Hollenbeck, A. R., Blair, A. E., Schatzkin, A. G., & Chen, H. (2011) · Diabetes Care · doi:10.2337/dc10-1922 · Cited by 282
Diabetes and Risk of Parkinson’s Disease
Cereda, E., Barichella, M., Pedrolli, C., Klersy, C., Cassani, E., Caccialanza, R., & Pezzoli, G. (2011) · Diabetes Care · doi:10.2337/dc11-1584 · Cited by 247
Obesity, diabetes, and risk of Parkinson's disease
Palacios, N., Gao, X., McCullough, M. L., Jacobs, E. J., Patel, A. V., Mayo, T. L., Schwarzschild, M. A., & Ascherio, A. (2011) · Movement Disorders · doi:10.1002/mds.23855 · Cited by 170
Neuroendocrine abnormalities in Parkinson's disease
Pablo‐Fernández, E. D., Breen, D. P., Bouloux, P. M., Barker, R. A., Foltynie, T., & Warner, T. T. (2016) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2016-314601 · Cited by 89
Self-citation
Integrative Network Analysis Unveils Convergent Molecular Pathways in Parkinson's Disease and Diabetes
Santiago, J. A., & Potashkin, J. A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0083940 · Cited by 79
Association between Parkinson's disease and diabetes: Data from NEDICES study
Pablo‐Fernández, E. D., Hidalgo, F. S., Benito‐León, J., & Bermejo‐Pareja, F. (2017) · Acta Neurologica Scandinavica · doi:10.1111/ane.12793 · Cited by 63

Show all 9 references

Research works printed but not linked: 1

National Institute for Health and Care Excellence. Parkinson's Disease in Adults. NICE Guideline NG71 [online]. Available at: nice.org.uk/guidance/NG71. Accessed August 1, 2017.

Sorted by citations

Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193
Parkinson Disease Epidemiology, Pathology, Genetics, and Pathophysiology
Simon, D. K., Tanner, C. M., & Brundin, P. (2020) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2019.08.002 · Cited by 1,114
Update of the MDS research criteria for prodromal Parkinson's disease
Heinzel, S., Berg, D., Gasser, T., Chen, H., Yao, C. W., Postuma, R. B., & the MDS Task Force on the Definition of Parkinson's Disease (2019) · Movement Disorders · doi:10.1002/mds.27802 · Cited by 804
Triggers, Facilitators, and Aggravators: Redefining Parkinson’s Disease Pathogenesis
Johnson, M., Stecher, B., Labrie, V., Brundin, L., & Brundin, P. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.09.007 · Cited by 321
Probiotic Clostridium butyricum ameliorated motor deficits in a mouse model of Parkinson’s disease via gut microbiota-GLP-1 pathway
Sun, J., Li, H., Jin, Y., Yu, J., Mao, S., Su, K.-P., Ling, Z., & Liu, J. (2021) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.10.014 · Cited by 264
Priming Microglia for Innate Immune Memory in the Brain
Neher, J. J., & Cunningham, C. M. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.001 · Cited by 263
Impairment of insulin signaling pathway PI3K/Akt/mTOR and insulin resistance induced AGEs on diabetes mellitus and neurodegenerative diseases: a perspective review
Ramasubbu, K., & Rajeswari, V. D. (2022) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-022-04587-x · Cited by 256
Diabetes medications and risk of Parkinson’s disease: a cohort study of patients with diabetes
Brauer, R., Wei, L., Ma, T., Athauda, D., Girges, C., Vijiaratnam, N., Auld, G., Whittlesea, C., Wong, I., & Foltynie, T. (2020) · Brain · doi:10.1093/brain/awaa262 · Cited by 233
The Association Between Type 2 Diabetes Mellitus and Parkinson’s Disease
Cheong, J. L. Y., Pablo‐Fernández, E. D., Foltynie, T., & Noyce, A. J. (2020) · Journal of Parkinson s Disease · doi:10.3233/jpd-191900 · Cited by 241
Self-citation
Type 2 Diabetes as a Determinant of Parkinson's Disease Risk and Progression
Chohan, H., Senkevich, K., Patel, R. K., Bestwick, J. P., Jacobs, B. M., Bandres Ciga, S., Gan‐Or, Z., & Noyce, A. J. (2021) · Movement Disorders · doi:10.1002/mds.28551 · Cited by 228
Self-citation
The energetic brain—A review from students to students
Bordone, M. P., Salman, M. M., Titus, H. E., Amini, E., Andersen, J. V., Chakraborti, B., Diuba, A. V., Dubouskaya, T. G., Ehrke, E., Espindola de Freitas, A., et al. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14829 · Cited by 205
“Interestingly, in a large retrospective cohort study, a higher prevalence of PD in patients with T2DM was detected (De Pablo-Fernandez et al. 2018).”
Background
Proteostasis of Islet Amyloid Polypeptide: A Molecular Perspective of Risk Factors and Protective Strategies for Type II Diabetes
Milardi, D., Gazit, E., Radford, S. E., Xu, Y., Gallardo, R. U., Caflisch, A., Westermark, G. T., Westermark, P., Rosa, C. L., & Ramamoorthy, A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00981 · Cited by 199
Dietary polyphenols: Regulate the advanced glycation end products-RAGE axis and the microbiota-gut-brain axis to prevent neurodegenerative diseases
Li, Y., Peng, Y., Shen, Y., Zhang, Y., Liu, L., & Yang, X. (2023) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2022.2076064 · Cited by 156
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Ethnic Variation in the Manifestation of Parkinson’s Disease: A Narrative Review
Ben-Joseph, A., Marshall, C. R., Lees, A. J., & Noyce, A. J. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191763 · Cited by 138
Self-citation
The Impact of Type 2 Diabetes in Parkinson's Disease
Athauda, D., Evans, J., Wernick, A., Virdi, G., Choi, M. L., Lawton, M., Vijiaratnam, N., Girges, C., Ben‐Shlomo, Y., Ismail, K., et al. (2022) · Movement Disorders · doi:10.1002/mds.29122 · Cited by 132
Insulin Resistance Promotes Parkinson’s Disease through Aberrant Expression of α-Synuclein, Mitochondrial Dysfunction, and Deregulation of the Polo-Like Kinase 2 Signaling
Hong, C.-T., Chen, K.-Y., Wang, W., Chiu, J.-Y., Wu, D., Chao, T.-Y., Hu, C.-J., Chau, K.-Y., & Bamodu, O. (2020) · Cells · doi:10.3390/cells9030740 · Cited by 133
An open label, non-randomized study assessing a prebiotic fiber intervention in a small cohort of Parkinson’s disease participants
Hall, D. A., Voigt, R. M., Cantu-Jungles, T. M., Hamaker, B., Engen, P. A., Shaikh, M., Raeisi, S., Green, S. J., Naqib, A., Forsyth, C. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-36497-x · Cited by 124
The Prion-Like Spreading of Alpha-Synuclein in Parkinson’s Disease: Update on Models and Hypotheses
Jan, A., Gonçalves, N. P., Vægter, C. B., Jensen, P. H., & Ferreira, N. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158338 · Cited by 133
Understanding the Links Between Cardiovascular Disease and Parkinson's Disease
Potashkin, J., Huang, X., Becker, C., Chen, H., Foltynie, T., & Marras, C. (2019) · Movement Disorders · doi:10.1002/mds.27836 · Cited by 121
The Relevance of Insulin Action in the Dopaminergic System
Fiory, F., Perruolo, G., Cimmino, I., Cabaro, S., Pignalosa, F. C., Miele, C., Bèguinot, F., Formisano, P., & Oriente, F. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00868 · Cited by 118
Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop
Arena, G., Sharma, K., Agyeah, G., Krüger, R., Grünewald, A., & Fitzgerald, J. C. (2022) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-022-01207-5 · Cited by 121
Body Mass Index, Diabetes, and the Risk of Parkinson's Disease
Jeong, S., Han, K., Kim, D., Rhee, S. Y., Jang, W., & Shin, D. W. (2019) · Movement Disorders · doi:10.1002/mds.27922 · Cited by 104
Widening the Spectrum of Risk Factors, Comorbidities, and Prodromal Features of Parkinson Disease
Schrag, A. E., Bohlken, J., Dammertz, L., Teipel, S. J., Hermann, W., Akmatov, M. K., Bätzing, J., & Holstiege, J. (2022) · JAMA Neurology · doi:10.1001/jamaneurol.2022.3902 · Cited by 96
Glucose metabolism impairment in Parkinson’s disease
Dai, C., Tan, C., Zhao, L., Liang, Y., Liu, G., Liu, H., Zhong, Y., Liu, Z., Mo, L., Liu, X., et al. (2023) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2023.110672 · Cited by 93
Diabetes Causes Dysfunctional Dopamine Neurotransmission Favoring Nigrostriatal Degeneration in Mice
Pérez‐Taboada, I., Alberquilla, S., Martín, E. D., Anand, R., Vietti‐Michelina, S., Tebeka, N. N., Cantley, J., Cragg, S. J., Moratalla, R., & Vallejo, M. (2020) · Movement Disorders · doi:10.1002/mds.28124 · Cited by 86
NF‐κB/NLRP3 inflammasome axis and risk of Parkinson's disease in Type 2 diabetes mellitus: A narrative review and new perspective
Alrouji, M., Al-Kuraishy, H. M., Al-Gareeb, A. I., Alexiou, A. T., Papadakis, M., Jabir, M. S., Saad, H. M., & Batiha, G. E. (2023) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.17784 · Cited by 87
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model
Lv, Y.-Q., Yuan, L., Sun, Y., Dou, H.-W., Su, J.-H., Hou, Z.-P., Li, J.-Y., & Li, W. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00288-z · Cited by 82
Semaglutide Attenuates Anxious and Depressive-Like Behaviors and Reverses the Cognitive Impairment in a Type 2 Diabetes Mellitus Mouse Model Via the Microbiota-Gut-Brain Axis
de Paiva, I. H. R., da Silva, R. S., Mendonça, I. P., Maciel, L. M., de Souza, J. R. B., & Peixoto, C. A. (2024) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-024-10142-w · Cited by 85
Neuroprotective Actions of Glucagon-Like Peptide-1 (GLP-1) Analogues in Alzheimer’s and Parkinson’s Diseases
Batista, A. F., Bodart‐Santos, V., Felice, F. G. D., & Ferreira, S. T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0593-6 · Cited by 78
Diabetes Mellitus and Parkinson's Disease: Shared Pathophysiological Links and Possible Therapeutic Implications
Hassan, A. T., Kandel, R. S., Mishra, R., Gautam, J., Alaref, A. A., & Jahan, N. (2020) · Cureus · doi:10.7759/cureus.9853 · Cited by 74
Type 2 Diabetes and Parkinson's Disease: A Focused Review of Current Concepts
Cullinane, P. W., Pablo‐Fernández, E. D., König, A., Outeiro, T. F., Jaunmuktane, Z., & Warner, T. T. (2022) · Movement Disorders · doi:10.1002/mds.29298 · Cited by 80
Self-citation
NLRP3 Inflammasomes in Parkinson’s disease and their Regulation by Parkin
Yan, Y., Fang, Y., Zheng, R., Pu, J., & Zhang, B. (2020) · Neuroscience · doi:10.1016/j.neuroscience.2020.08.004 · Cited by 72
Diabetes mellitus, prediabetes and the risk of Parkinson’s disease: a systematic review and meta-analysis of 15 cohort studies with 29.9 million participants and 86,345 cases
Aune, D., Schlesinger, S., Mahamat‐Saleh, Y., Zheng, B., Udeh‐Momoh, C. T., & Middleton, L. T. (2023) · European Journal of Epidemiology · doi:10.1007/s10654-023-00970-0 · Cited by 73
Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia
Heimke, M., Lenz, F., Rickert, U., Lucius, R., & Cossais, F. (2022) · Cells · doi:10.3390/cells11193107 · Cited by 77
A nationwide cohort study on diabetes severity and risk of Parkinson disease
Han, K., Kim, B., Lee, S. H., & Kim, M. K. (2023) · npj Parkinson's Disease · doi:10.1038/s41531-023-00462-8 · Cited by 67
Diabetes Mellitus and Parkinson’s Disease: A Systematic Review and Meta-Analyses
Komici, K., Femminella, G. D., Bencivenga, L., Rengo, G., & Pagano, G. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-212725 · Cited by 67
Animal Models of Metabolic Disorders in the Study of Neurodegenerative Diseases: An Overview
Bem, A. F. D., Krolow, R., Farias, H. R., de Rezende, V. L., Gelain, D. P., Moreira, J. C. F., Duarte, J. M. N., & de Oliveira, J. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.604150 · Cited by 69
Melatonin as a Chronobiotic and Cytoprotective Agent in Parkinson’s Disease
Perez‐Lloret, S., & Cardinali, D. P. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.650597 · Cited by 66
Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases
Sousa, L., Guarda, M., Meneses, M. J., Macedo, M. P., & Miranda, H. V. (2021) · The Journal of Pathology · doi:10.1002/path.5777 · Cited by 67
Analysis of the Relationship between Type II Diabetes Mellitus and Parkinson’s Disease: A Systematic Review
Maluf, F. C., Feder, D., & Carvalho, A. A. D. S. (2019) · Parkinson s Disease · doi:10.1155/2019/4951379 · Cited by 65
Diabetes: a tipping point in neurodegenerative diseases
Santiago, J. A., Karthikeyan, M., Lackey, M., Villavicencio, D., & Potashkin, J. A. (2023) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2023.09.005 · Cited by 65
Type 2 Diabetes (T2DM) and Parkinson’s Disease (PD): a Mechanistic Approach
Sabari, S. S., Balasubramani, K., Iyer, M., Babu, H. W. S., Venkatesan, D., Gopalakrishnan, A. V., Narayanaswamy, A., Kumar, N. S., & Vellingiri, B. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03359-y · Cited by 64
Two Birds One Stone: The Neuroprotective Effect of Antidiabetic Agents on Parkinson Disease—Focus on Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors
Lin, K.-J., Wang, T., Chen, S., Lin, K.-L., Liou, C., Lan, M., Chuang, Y., Chuang, J., Wang, P., Lee, J., et al. (2021) · Antioxidants · doi:10.3390/antiox10121935 · Cited by 64
Drug Repurposing in Parkinson’s Disease
Athauda, D. S., & Foltynie, T. (2018) · CNS Drugs · doi:10.1007/s40263-018-0548-y · Cited by 59
Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.02.010 · Cited by 58
Association of Antiviral Therapy With Risk of Parkinson Disease in Patients With Chronic Hepatitis C Virus Infection
Lin, W.-Y., Lin, M., Weng, Y.-H., Yeh, T., Lin, Y., Fong, P., Wu, Y., Lu, C.-S., Chen, R., & Huang, Y. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.1368 · Cited by 57
The role of nutrition on Parkinson’s disease: a systematic review
Bianchi, V. E., Rizzi, L., & Somaa, F. A. (2022) · Nutritional Neuroscience · doi:10.1080/1028415x.2022.2073107 · Cited by 60
Prediabetes, type 2 diabetes mellitus and risk of Parkinson’s disease: A population-based cohort study
Sánchez‐Gómez, A., Díaz, Y., Duarte‐Salles, T., Compta, Y., & Martı́, M. J. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.06.002 · Cited by 54
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned
Hung, A. Y., & Schwarzschild, M. A. (2020) · Neurotherapeutics · doi:10.1007/s13311-020-00964-w · Cited by 53
Glucagon-Like Peptide-1 Receptor Agonist Ameliorates 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine (MPTP) Neurotoxicity Through Enhancing Mitophagy Flux and Reducing α-Synuclein and Oxidative Stress
Lin, T., Lin, K.-J., Lin, H., Lin, K.-L., Lan, M., Wang, P., Wang, T., Wang, F., Tsai, P.-C., Liou, C., et al. (2021) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2021.697440 · Cited by 52
Parkinson's disease and glucose metabolism impairment
Chen, L., Wang, C., Qin, L., & Zhang, H. (2025) · Translational Neurodegeneration · doi:10.1186/s40035-025-00467-8 · Cited by 51
Diabetes, Glycated Hemoglobin ( HbA1c) , and Neuroaxonal Damage in Parkinson's Disease ( MARK‐PD Study )
Uyar, M., Lezius, S., Buhmann, C., Pötter‐Nerger, M., Schulz, R. J., Meier, S., Gerloff, C. P., Kühle, J., & Choe, C. (2022) · Movement Disorders · doi:10.1002/mds.29009 · Cited by 46
Parkinson’s Disease and Sugar Intake—Reasons for and Consequences of a Still Unclear Craving
Haas, J., Berg, D., Bosy‐Westphal, A., & Schaeffer, E. (2022) · Nutrients · doi:10.3390/nu14153240 · Cited by 46
Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal
von Linstow, C. U., Gan‐Or, Z., & Brundin, P. (2020) · Translational Neurodegeneration · doi:10.1186/s40035-020-00218-x · Cited by 45
Risky behaviors and Parkinson disease
Grover, S., Del, G. M. F., Kasten, M., Klein, C., Lill, C. M., & König, I. R. (2019) · Neurology · doi:10.1212/wnl.0000000000008245 · Cited by 48
Peripheral insulin and amylin levels in Parkinson's disease
Sánchez-Gómez, A., Alcarraz-Vizán, G., Fernández, M., Fernández-Santiago, R., Ezquerra, M., Cámara, A., Serrano, M., Novials, A., Muñoz, E., Valldeoriola, F., et al. (2020) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2020.08.018 · Cited by 44
Dysfunction of the neurovascular unit in diabetes-related neurodegeneration
Yan, C., Zhou, Y., Chen, Q., Luo, Y., Zhang, J. H., Huang, H., & Shao, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110656 · Cited by 47
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
Foltynie, T., & Athauda, D. S. (2019) · Progress in brain research · doi:10.1016/bs.pbr.2019.10.008 · Cited by 46
Faster disease progression in Parkinson’s disease with type 2 diabetes is not associated with increased α‐synuclein, tau, amyloid‐β or vascular pathology
Pablo‐Fernández, E. D., Courtney, R. J., Rockliffe, A., Gentleman, S., Holton, J. L., & Warner, T. T. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12728 · Cited by 43
Self-citation
Living with the enemy: from protein-misfolding pathologies we know, to those we want to know
Emwas, A.-H. M., Alghrably, M., Dhahri, M., Sharfalddin, A. A., Alsiary, R., Jaremko, M., Faa, G., Campagna, M., Congiu, T., Piras, M., et al. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101391 · Cited by 43
Neuroprotective effects of GLP-1 class drugs in Parkinson’s disease
Lv, D., Feng, P., Guan, X., Liu, Z., Li, D., Xue, C., Bai, B., & Hölscher, C. (2024) · Frontiers in Neurology · doi:10.3389/fneur.2024.1462240 · Cited by 46
Chronic Systemic Inflammation Exacerbates Neurotoxicity in a Parkinson’s Disease Model
Ugalde‐Muñiz, P., Fetter-Pruneda, I., Navarro, L., García, E., & Chavarría, A. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/4807179 · Cited by 42
Diabetes mellitus and Parkinson’s disease: dangerous liaisons between insulin and dopamine
de Iuliis, A., Montinaro, E., Fatati, G., Plebani, M., & Colosimo, C. (2021) · Neural Regeneration Research · doi:10.4103/1673-5374.320965 · Cited by 37
Shared perturbations in the metallome and metabolome of Alzheimer’s, Parkinson’s, Huntington’s, and dementia with Lewy bodies: A systematic review
Scholefield, M., Unwin, R. D., & Cooper, G. J. S. (2020) · Ageing Research Reviews · doi:10.1016/j.arr.2020.101152 · Cited by 39
Euglycemia Indicates Favorable Motor Outcome in Parkinson's Disease
Markaki, I., Ntetsika, T., Sorjonen, K., Svenningsson, P., & for the BioPark Study Group (2021) · Movement Disorders · doi:10.1002/mds.28545 · Cited by 42
Association between diabetes mellitus and risk of Parkinson's disease: A prisma‐compliant meta‐analysis
Liu, W., & Tang, J. (2021) · Brain and Behavior · doi:10.1002/brb3.2082 · Cited by 39
α-Synuclein promotes IAPP fibril formation in vitro and β-cell amyloid formation in vivo in mice
Mucibabic, M., Steneberg, P., Lidh, E., Straseviçiene, J., Ziółkowska, A., Dahl, U., Lindahl, E., & Edlund, H. (2020) · Scientific Reports · doi:10.1038/s41598-020-77409-z · Cited by 41
Liraglutide Regulates Mitochondrial Quality Control System Through PGC-1α in a Mouse Model of Parkinson’s Disease
Wu, P., Dong, Y., Chen, J., Guan, T., Cao, B., Zhang, Y., Qi, Y., Guan, Z., & Wang, Y. (2022) · Neurotoxicity Research · doi:10.1007/s12640-021-00460-9 · Cited by 44
Hormone‐related diseases and prostate cancer: An English national record linkage study
Watts, E. L., Goldacre, R., Key, T. J., Allen, N. E., Travis, R. C., & Perez‐Cornago, A. (2019) · International Journal of Cancer · doi:10.1002/ijc.32808 · Cited by 35
Self-citation
Potential Role of Akkermansia muciniphila in Parkinson’s Disease and Other Neurological/Autoimmune Diseases
Fang, X., Li, F., & Hong, D. (2021) · Current Medical Science · doi:10.1007/s11596-021-2464-5 · Cited by 37
Pioglitazone and statins lower incidence of Parkinson disease in patients with diabetes mellitus
Chang, Y., Yen, S., Chang, Y. ‐., Wu, W. ‐., & Lin, K. (2020) · European Journal of Neurology · doi:10.1111/ene.14542 · Cited by 34
Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease
Dong, D., Xie, J.-X., & Wang, J. (2019) · Neuroscience Bulletin · doi:10.1007/s12264-019-00407-3 · Cited by 34
PKM2-mediated neuronal hyperglycolysis enhances the risk of Parkinson's disease in diabetic rats
Ya, Z., Wang, Y., Wu, Y., Tao, C., Xu, R., Chen, Y., Qian, L., Xu, T., & Lian, X. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.11.006 · Cited by 33
NOX-induced oxidative stress is a primary trigger of major neurodegenerative disorders
Zilberter, Y., Tabuena, D. R., & Zilberter, M. Y. (2023) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2023.102539 · Cited by 35
Repositioning and development of new treatments for neurodegenerative diseases: Focus on neuroinflammation
Arbo, B. D., Schimith, L. E., dos Santos, M. G., & Hort, M. A. (2022) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2022.174800 · Cited by 33
Gastrodin Ameliorates Motor Learning Deficits Through Preserving Cerebellar Long-Term Depression Pathways in Diabetic Rats
Deng, C.-K., Mu, Z., Miao, Y.-H., Liu, Y., Zhou, L., Huang, Y., Zhang, F., Wang, Y.-Y., Yang, Z.-H., Qian, Z., et al. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01239 · Cited by 32
The NLRP3 inflammasome as a bridge between neuro-inflammation in metabolic and neurodegenerative diseases
Söderbom, G., & Zeng, B. (2020) · International review of neurobiology · doi:10.1016/bs.irn.2020.03.023 · Cited by 32
Type 2 diabetes mellitus and neurodegenerative disorders: The mitochondrial connection
Baduini, I. R., Castro-Vildosola, J., Kavehmoghaddam, S., Kiliç, F., Nadeem, S. A., Nizama, J. J., Rowand, M. A., Annapureddy, D., Bryan, C.-A., Do, L. H., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107439 · Cited by 33
Neuroprotective and Anti-Inflammatory Effects of Pioglitazone on Parkinson's Disease: A Comprehensive Narrative Review of Clinical and Experimental Findings
Zamanian, M. Y., Terefe, E. M., Taheri, N., Kujawska, M., Tork, Y. J., Abdelbasset, W. K., Shoukat, S., Opulencia, M. J. C., Heidari, M., & Alesaeidi, ‬. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527322666221005122408 · Cited by 30
Pioglitazone use and Parkinson’s disease: a retrospective cohort study in Taiwan
Wu, H.-F., Kao, L., Shih, J., Kao, H., Chou, Y., Li, I., & Kao, S. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-023302 · Cited by 30
Glycation of α-synuclein amplifies the binding with glyceraldehyde-3-phosphate dehydrogenase
Semenyuk, P. I., Barinova, K. V., & Muronetz, V. I. (2019) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.01.064 · Cited by 30
Diabetes, insulin and new therapeutic strategies for Parkinson’s disease: Focus on glucagon-like peptide-1 receptor agonists
Labandeira, C. M., Bau, A. F., Ron, D. A., Muñoz, A., Losada, G. A., Koukoulis, A., Romero-López, J., & Rodriguez-Perez, A. I. (2021) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2021.100914 · Cited by 28
Cardioselective peripheral noradrenergic deficiency in Lewy body synucleinopathies
Lamotte, G. J., Holmes, C. S., Sullivan, P., Lenka, A., & Goldstein, D. S. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51243 · Cited by 27
Reduced white matter microstructural integrity in prediabetes and diabetes: A population-based study
Jing, J., Zhou, Y., Pan, Y., Cai, X., Zhu, W., Zhang, Z., Li, Z., Liu, C., Meng, X., Cheng, J., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104144 · Cited by 29
Semaglutide Protects against 6‐OHDA Toxicity by Enhancing Autophagy and Inhibiting Oxidative Stress
Liu, D.-X., Zhao, C.-S., Wei, X., Ma, Y.-P., & Wu, J.-K. (2022) · Parkinson s Disease · doi:10.1155/2022/6813017 · Cited by 33
Diabetes Mellitus is Associated with a Higher Relative Risk for Parkinson’s Disease in Women than in Men
Deischinger, C., Dervić, E., Kaleta, M., Klimek, P., & Kautzky‐Willer, A. (2021) · Journal of Parkinson s Disease · doi:10.3233/jpd-202486 · Cited by 26
Glycation of α-synuclein hampers its binding to synaptic-like vesicles and its driving effect on their fusion
Uceda, A. B., Frau, J., Vilanova, B., & Adrover, M. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04373-4 · Cited by 25
Waist circumference and risk of Parkinson’s disease
Park, K., Nam, G. E., Han, K., Park, H.-K., & Hwang, H. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00353-4 · Cited by 27
Disrupted Mitochondrial and Metabolic Plasticity Underlie Comorbidity between Age-Related and Degenerative Disorders as Parkinson Disease and Type 2 Diabetes Mellitus
Juárez‐Flores, D. L., Ezquerra, M., González‐Casacuberta, I., Ormazábal, A., Morén, C., TOLOSA, E. S., Fucho, R., Guitart‐Mampel, M., Casado, M., Valldeoriola, F., et al. (2020) · Antioxidants · doi:10.3390/antiox9111063 · Cited by 24
Convergent Molecular Pathways in Type 2 Diabetes Mellitus and Parkinson’s Disease: Insights into Mechanisms and Pathological Consequences
Sandeep, X. X. X. X., Ahmad, M. H., Rani, L., & Mondal, A. C. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02867-7 · Cited by 24
Diabetes, BMI, and Parkinson's
Foltynie, T., & Athauda, D. S. (2020) · Movement Disorders · doi:10.1002/mds.27941 · Cited by 24
Fasting plasma glucose variability in midlife and risk of Parkinson's disease: A nationwide population-based study
Chung, H. S., Lee, J. S., Kim, N. H., Roh, E., Lee, Y.-B., Hong, S. H., Yu, J. H., Kim, N. H., Yoo, H. J., Seo, J. A., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.006 · Cited by 23
Ultrastructural Remodeling of the Neurovascular Unit in the Female Diabetic db/db Model—Part I: Astrocyte
Hayden, M. R., Grant, D. G., Aroor, A. R., & DeMarco, V. G. (2018) · Neuroglia · doi:10.3390/neuroglia1010015 · Cited by 23
Variation in responses to incretin therapy: Modifiable and non-modifiable factors
Austin, G. O., & Tomás, A. (2023) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2023.1170181 · Cited by 24
Targeting Glucose Metabolism: A Novel Therapeutic Approach for Parkinson’s Disease
Tanvir, A., Jo, J., & Park, S. M. (2024) · Cells · doi:10.3390/cells13221876 · Cited by 52
α-Synuclein Regulates Peripheral Insulin Secretion and Glucose Transport
Wijesekara, N., Ahrens, R., Wu, L., Langman, T., Tandon, A., & Fraser, P. E. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.665348 · Cited by 22
A crazy trio in Parkinson's disease: metabolism alteration, α-synuclein aggregation, and oxidative stress
Li, S., Liu, Y., Lu, S., Xu, J., Liu, X., Yang, D., Yang, Y., Hou, L., & Li, N. (2024) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-024-04985-3 · Cited by 23
Are rises in Electro-Magnetic Field in the human environment, interacting with multiple environmental pollutions, the tipping point for increases in neurological deaths in the Western World?
Pritchard, C. W., Silk, A., & Hansen, L. K. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.03.018 · Cited by 21
Impact of diabetes mellitus type two on incidence and progression of Parkinson’s disease: a systematic review of longitudinal patient cohorts
Stockmann, O., Ye, L., Greten, S., Chemodanow, D., Wegner, F., & Klietz, M. (2025) · Journal of Neural Transmission · doi:10.1007/s00702-025-02882-7 · Cited by 20

Authors: De Pablo-Fernandez, E., Goldacre, R., Pakpoor, J., Noyce, A. J., & Warner, T. T.
Affiliations: From the Reta Lila Weston Institute of Neurological Studies, Department of Molecular Neurosciences (E.D.P.-F., A.J.N., T.T.W.), and Queen Square Brain Bank for Neurological Disorders (E.D.P.-F., T.T.W.), UCL Institute of Neurology, London; Unit of Health-Care Epidemiology (R.G., J.P.), Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield Department of Population Health, University of Oxford; and Preventive Neurology Unit (A.J.N.), Wolfson Institute of Preventive...
Queen Mary University of London (GB)
ORCID: Goldacre, Raph
Noyce, Alastair J.
Warner, Thomas T.
Venue: Neurology
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2018-07-10
Volume: 91
Issue: 2
Pages: e139-e142
ISSN: 0028-3878 (ISSN-L)
1526-632X
DOI: 10.1212/wnl.0000000000005771
OpenAlex: W2807806732
Cited by: 242
References: 9
Citations by year: 2026: 23 · 2025: 21 · 2024: 36 · 2023: 28 · 2022: 29 · 2021: 35 · 2020: 34 · 2019: 26 · 2018: 9
FWCI: 17.62
Type: journal article
Language: en
Open access: closed
Locations: Neurology (publishedVersion)
PubMed (publishedVersion)
UCL Discovery (University College London) (submittedVersion)
Funders: Prothena
Barts Charity (MGU0364)
National Institute for Health and Care Research (RNC/035/02)
Parkinson's UK
Brain Research Trust
University College London
University of Oxford
Britannia Pharmaceuticals
Medical Research Council (MR/L023784/2, MR/L023784/1)
NIHR Oxford Biomedical Research Centre
Topics: Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
Keywords: type 2 diabetes, Parkinson's disease, risk factors, complicated diabetes, young adults, pathogenic pathways
MeSH terms: Adult, Age Factors, Aged, Diabetes Mellitus, Type 2, England, Female, Humans, Male, Middle Aged, Parkinson Disease, Retrospective Studies, Risk Factors, Comorbidity, Case-Control Studies

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks